The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve intravitreal dexamethasone as a treatment option for the treatment of Diabetic Macular Oedema in line with NICE TA824. A Diabetic Macular Oedema (DMO) treatment pathway was also agreed by the APC and is attached for information.
Intravitreal dexamethasone will be considered RED on the traffic light system.
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
The PCN decision of October 2015 was reviewed in May 2018 in regards to frequency of injections and the PCN agreed to the Ophthalmology Network proposal to allow some patients to have injections more frequently than every 6 months (no more frequently than 4 monthly).
Please see below for further information
